📊 FEED Key Takeaways
Is ENvue Medical, Inc. (FEED) a Good Investment?
ENvue Medical exhibits severe fundamental deterioration with negative gross margins (-8.4%), indicating unsustainable unit economics where losses accumulate on every sale. Operating cash burn of $4.3M annually against only $2.2M cash reserves provides less than 6 months of runway, while near-zero revenue ($653K) and liquidity stress (0.90x current ratio) signal existential operational challenges.
ENvue Medical shows modest top-line growth, but the business remains fundamentally weak with very low gross margin, extremely negative operating leverage, and free cash flow burn that far exceeds revenue. The balance sheet is not heavily levered, but sub-1.0 liquidity ratios and ongoing operating losses suggest funding risk and poor growth quality unless margins and cash burn improve materially.
ENvue Medical, Inc. Key Strengths (FEED)
- Low debt burden with 0.04x debt-to-equity ratio providing financial flexibility
- Improved EPS trend with 80.6% YoY improvement suggesting losses are narrowing
- Stockholders' equity of $32M provides base assets and dilution cushion
- Revenue grew 12.0% year over year, indicating some commercial traction
- Low debt burden with debt/equity of 0.03x limits financial leverage risk
- Positive equity base of $42.46M provides some balance sheet support
FEED Stock Risks: ENvue Medical, Inc. Investment Risks
- Negative gross margin of -8.4% indicates broken unit economics with losses on every sale
- Operating cash outflow of $4.3M with only $2.2M cash creates sub-6-month runway
- Liquidity crisis emerging with current ratio of 0.90x and quick ratio of 0.57x
- Minimal revenue base of $653K suggests complete lack of market traction or commercialization failure
- Negative operating margin of -568.3% reflects severe operational dysfunction
- Operating margin of -360.3% and net margin of -238.0% show the business model is not close to self-sustaining
- Negative operating cash flow of $6.70M and free cash flow margin of -300.4% indicate severe cash burn
- Current ratio of 0.86x and quick ratio of 0.67x point to near-term liquidity pressure
Key Metrics to Watch
- Gross margin trend and path to positive unit economics
- Cash runway depletion rate and next capital raise timeline
- Revenue growth trajectory and customer acquisition metrics
- Operating cash flow stabilization and burn rate reduction
- Quarterly cash position changes and liquidity developments
- Gross margin trend and whether revenue growth is translating into operating leverage
- Cash burn relative to cash balance, especially operating cash flow and current ratio
ENvue Medical, Inc. (FEED) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
FEED Profit Margin, ROE & Profitability Analysis
FEED vs Healthcare Sector: How ENvue Medical, Inc. Compares
How ENvue Medical, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is ENvue Medical, Inc. Stock Overvalued? FEED Valuation Analysis 2026
Based on fundamental analysis, ENvue Medical, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
ENvue Medical, Inc. Balance Sheet: FEED Debt, Cash & Liquidity
FEED Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: ENvue Medical, Inc.'s revenue has grown significantly by 51% over the 5-year period, indicating strong business expansion. The most recent EPS of $-137.30 indicates the company is currently unprofitable.
FEED Revenue Growth, EPS Growth & YoY Performance
FEED Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $653.0K | -$1.9M | $-6.88 |
| Q3 2025 | $376.0K | $510.0K | $-0.91 |
| Q2 2025 | $494.0K | -$688.0K | $-1.03 |
| Q1 2025 | $921.0K | -$588.0K | $2.38 |
| Q3 2024 | $376.0K | -$727.0K | $-0.36 |
| Q2 2024 | $294.0K | -$688.0K | $-0.25 |
| Q1 2024 | $354.0K | -$588.0K | $-0.23 |
| Q3 2023 | $97.0K | $500.0K | $-0.42 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
ENvue Medical, Inc. Dividends, Buybacks & Capital Allocation
FEED SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for ENvue Medical, Inc. (CIK: 0001326706)
📋 Recent SEC Filings
❓ Frequently Asked Questions about FEED
What is the AI rating for FEED?
ENvue Medical, Inc. (FEED) has a Combined AI Grade of D from Claude (D) and ChatGPT (D) with 88% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are FEED's key strengths?
Claude: Low debt burden with 0.04x debt-to-equity ratio providing financial flexibility. Improved EPS trend with 80.6% YoY improvement suggesting losses are narrowing. ChatGPT: Revenue grew 12.0% year over year, indicating some commercial traction. Low debt burden with debt/equity of 0.03x limits financial leverage risk.
What are the risks of investing in FEED?
Claude: Negative gross margin of -8.4% indicates broken unit economics with losses on every sale. Operating cash outflow of $4.3M with only $2.2M cash creates sub-6-month runway. ChatGPT: Operating margin of -360.3% and net margin of -238.0% show the business model is not close to self-sustaining. Negative operating cash flow of $6.70M and free cash flow margin of -300.4% indicate severe cash burn.
What is FEED's revenue and growth?
ENvue Medical, Inc. reported revenue of $653.0K.
Does FEED pay dividends?
ENvue Medical, Inc. does not currently pay dividends.
Where can I find FEED SEC filings?
Official SEC filings for ENvue Medical, Inc. (CIK: 0001326706) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is FEED's EPS?
ENvue Medical, Inc. has a diluted EPS of $-6.88.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is FEED's fundamental grade?
Based on our AI fundamental analysis in June 2026, ENvue Medical, Inc. has a D grade with 88% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is FEED stock overvalued or undervalued?
Valuation metrics for FEED: ROE of -11.9% (sector avg: 15%), net margin of -585.3% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is FEED's AI grade for 2026?
Our dual AI analysis gives ENvue Medical, Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is FEED's free cash flow?
ENvue Medical, Inc.'s operating cash flow is $-4.3M, with capital expenditures of $17.0K. FCF margin is -662.9%.
How does FEED compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -585.3% (avg: 12%), ROE -11.9% (avg: 15%), current ratio 0.90 (avg: 2).